IN-002
Respiratory Syncytial Virus (RSV)
Pre-INDActive
Key Facts
About Inhalon Biopharma
Inhalon Biopharma is pioneering a novel inhaled antibody platform that leverages 'muco-trapping' technology to treat acute respiratory infections directly in the lung. Founded in 2016 and based in San Diego, the private company has advanced its lead candidate, IN-006 for COVID-19, into Phase 1b studies and secured significant non-dilutive grant funding from U.S. government agencies. With a focus on enabling at-home, test-to-treat models, Inhalon aims to address a major unmet need in respiratory care by developing fast-acting, locally delivered therapeutics.
View full company profileTherapeutic Areas
Other Respiratory Syncytial Virus (RSV) Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical Program | Biotron | Preclinical |
| BLB201 | CyanVac | Phase 1/2 |
| AI Programme - RSV | Poolbeg Pharma | Discovery |
| BP-002 | BioNet Asia | Phase 1 |
| Oral RSV Vaccine | Vaxart | Preclinical/Phase 1 |